Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the arthralgia market?

The market size for arthralgia has seen considerable growth in the past few years. The market, which was valued at $5.20 billion in 2024, is projected to increase to $5.64 billion in 2025, showcasing a compound annual growth rate (CAGR) of 8.5%. This surge in growth during the historic period can be attributed to a higher incidence of autoimmune diseases, a rise in associated risk factors, an increased obesity rate, a growing prevalence of arthralgia, and a heightened occurrence of joint disorders.

What will be the arthralgia market size in the future?

Projected to experience significant growth in the coming years, the arthralgia market is anticipated to expand to $7.73 billion by 2029, expanding at a compound annual growth rate (CAGR) of 8.2%. The predicted growth during the forecast period is due to factors such as increased arthralgia awareness, a growing elderly population, improvements in healthcare infrastructure, a surging demand for minimally invasive procedures, and an increasing prevalence of sports-related injuries. The forecasting period is also expected to witness crucial trends including the incorporation of digital health solutions, the introduction of new therapies, advancement in cellular therapies, strides in medical technology, and increased commitment to research and development.

Get your arthralgia market report here!

https://www.thebusinessresearchcompany.com/report/arthralgia-global-market-report

What main drivers are fueling expansion in the arthralgia market?

The surge in cases of rheumatoid arthritis is predicted to impel the progress of the arthralgia market in the future. Rheumatoid arthritis, a chronic autoimmune disorder, significantly affects joints, resulting in inflammation, pain, and potential joint damage. The escalation in rheumatoid arthritis cases is ascribed to older populations, genetic predispositions, lifestyle modifications, and environmental triggers like smoking and pollution. Rheumatoid arthritis (RA) induces arthralgia by inciting chronic inflammation in the joints, which results in pain, stiffness, and progressive destruction. For example, Arthritis Australia, a non-profit organization based in Australia, vouched in February 2024 that by 2040, cases of arthritis in Australia are projected to climb to 5.39 million from 4.11 million in 2025, with osteoarthritis ascending to 3.11 million from 2.35 million and rheumatoid arthritis amounting to 748,721. Consequently, the surge in rheumatoid arthritis cases is fuelling the expansion of the arthralgia market.

What key areas define the segmentation of the global arthralgia market?

The arthralgia market covered in this report is segmented –

1) By Cause: Osteoarthritis, Rheumatoid Arthritis, Gout, Psoriatic Arthritis, Lupus, Injuries, Infections, Other Causes

2) By Treatment Type: Medications, Therapies, Surgical Interventions, Lifestyle And Home Remedies

3) By Route Of Administration: Oral, Injectable, Topical, Transdermal

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End User: Hospital, Clinics, Homecare Settings, Rehabilitation Centers

Subsegments:

1) By Osteoarthritis: Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis, Spine Osteoarthritis, Shoulder Osteoarthritis

2) By Rheumatoid Arthritis: Seropositive Rheumatoid Arthritis, Seronegative Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Early-Onset Rheumatoid Arthritis

3) By Gout: Primary Gout, Secondary Gout, Gouty Arthritis

4) By Psoriatic Arthritis: Symmetric Psoriatic Arthritis, Asymmetric Psoriatic Arthritis, Psoriatic Spondylitis, Distal Interphalangeal Predominant Psoriatic Arthritis

5) By Lupus: Systemic Lupus Erythematosus (SLE), Discoid Lupus Erythematosus, Drug-induced Lupus, Neonatal Lupus

6) By Injuries: Sports-related Injuries, Trauma and Fractures, Sprains and Strains, Tendon or Ligament Damage

7) By Infections: Septic Arthritis, Viral Arthritis, Bacterial Infections, Fungal Infections

8) By Other Causes: Fibromyalgia, Overuse Injuries, Sarcoidosis, Ankylosing Spondylitis, Crystal-induced Arthritis

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21104&type=smp

Who are the dominant players expanding their reach in the arthralgia market?

Major companies operating in the arthralgia market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., UCB S.A., Hikma Pharmaceuticals PLC, Ferring Pharmaceuticals, KD Pharma Group S.A., SI-BONE Inc., Xalud Therapeutics Inc., Incannex Healthcare Limited, Cytonics Corporation, Vitazan Herbs and Vitamins Inc.

What key trends are currently impacting the arthralgia market’s development?

The primary players in the arthralgia market are honing in on the creation of innovatory therapies, such as RMAT-recognized gene therapy, intending to offer patients superior treatments that promote long-lasting relief from pain and enhanced joint movement. RMAT-approved gene therapy delineates a treatment that has obtained the Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, a process that promotes the faster advancement and evaluation of revolutionary gene therapies aimed at severe or potentially fatal conditions. For example, in March 2024, Pacira BioSciences Inc., an American pharmaceutical firm, earned the Regenerative Medicine Advanced Therapy (RMAT) recognition for its product, PCRX-201 (enekinragene inzadenovec), from the U.S. Food and Drug Administration (FDA). This groundbreaking, intra-articular gene therapy candidate utilizes a helper-dependent adenovirus (HDAd) to address knee osteoarthritis and is created to generate interleukin-1 receptor antagonists (IL-1Ra). Upon receipt of the FDA’s inaugural RMAT recognition for a gene therapy focused on osteoarthritis, Pacira expressed its elation and spotlighted the encouraging initial clinical findings that suggest that PCRX-201 may potentially modify the disease.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21104

Which regions are emerging as leaders in the arthralgia market?

North America was the largest region in the arthralgia market in 2024. The regions covered in the arthralgia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Antidotes Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antidotes-global-market-report

Antifungals Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report

Kidney Cancer Drugs Global Market Report 2025

https://thebusinessresearchcompany.com/report/kidney-cancer-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: